Effects of Erythropoietin on Glucose Metabolism

 

 Buy Article Permissions and Reprints

Abstract

We purposed to determine the impact of erythropoietin on altering glucose metabolism in the settings of in vitro and in vivo experiments. The acute effect of erythropoietin on lowering blood glucose levels was studied in animal experiments. In [³H]-deoxy-d-glucose isotope studies we measured glucose uptake with insulin and erythropoietin using 3T3-L1 cells cultured under normal or high glucose conditions. Altered activation of Akt and ERK pathways was evaluated in immunoblot analyses. Immunocytochemistry was conducted to determine the glucose transporter 4 translocation to the plasma membrane. Addition of erythropoietin significantly lowered blood glucose levels in vivo in rats. The glucose uptake was markedly increased by erythropoietin treatment (at concentrations 0.15, 0.3, and 0.625 ng/ml) in adipocytes grown in high glucose medium (p<0.05), but it remained unaltered in cells under normal glucose conditions. Significant increase of phosphorylation of ERK and Akt was detected due to erythropoietin (p<0.05). Co-administration of erythropoietin and insulin resulted in higher phosphorylation of Akt and [³H]-deoxy-d-glucose uptake in adipocytes than insulin treatment alone. We found that erythropoietin induced the trafficking of glucose transporter 4 to the plasma membrane. Our data showed that erythropoietin significantly decreased blood glucose levels both in vivo and in vitro, in part, by increasing glucose uptake via the activation of Akt pathway. Preliminary data revealed that adipocytes most likely exhibit a specific receptor for erythropoietin.

• References

• 1 Morse BS, Stohlman Jr F. Regulation of erythropoiesis. 18. The effect of incristine and erythropoietin on bone marrow. J Clin Invest 1966; 45: 1241-1250
  CrossrefPubMedGoogle Scholar
• 2 Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31
  CrossrefPubMedGoogle Scholar
• 3 Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993; 81: 2223-2236
  PubMedGoogle Scholar
• 4 Wojchowski DM, Sathyanarayana P, Dev A. Erythropoietin receptor response circuits. Curr Opin Hematol 2010; 17: 169-176
  PubMedGoogle Scholar
• 5 Fu P, Jiang X, Arcasoy MO. Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun 2009; 13; 379: 696-701
  CrossrefPubMedGoogle Scholar
• 6 Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239: 494-500
  CrossrefPubMedGoogle Scholar
• 7 Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116
  PubMedGoogle Scholar
• 8 Lewczuk P, Hasselblatt M, Kamrowski-Kruck H, Heyer A, Unzicker C, Sirén AL, Ehrenreich H. Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin. Neuroreport 2000; 11: 3485-3488
  CrossrefPubMedGoogle Scholar
• 9 Nagai A, Nakagawa E, Choi HB. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60: 386-392
  PubMedGoogle Scholar
• 10 Fenjves ES, Ochoa MS, Cabrera O, Mendez AJ, Kenyon NS, Inverardi L, Ricordi C. Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation 2003; 75: 1356-1360
  CrossrefPubMedGoogle Scholar
• 11 Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Blackwell KL. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006; 5: 356-361
  CrossrefPubMedGoogle Scholar
• 12 Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, Liu X, Wu H, Carmichael ST. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-1274
  CrossrefPubMedGoogle Scholar
• 13 Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640
  CrossrefPubMedGoogle Scholar
• 14 Lu KY, Ching LC, Su KH, Yu YB, Kou YR, Hsiao SH, Huang YC, Chen CY, Cheng LC, Pan CC, Lee TS. Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor alpha. Circulation 2010; 121: 1828-1837
  CrossrefPubMedGoogle Scholar
• 15 Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, Gehl J. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009; 12; 4: e5894
  CrossrefPubMedGoogle Scholar
• 16 Allegra V, Mengozzi G, Martimbianco L, Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol 1996; 16: 304-308
  CrossrefPubMedGoogle Scholar
• 17 Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 1999; 101: 823-828
  PubMedGoogle Scholar
• 18 Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, Shino T, Yamada C, Nagaoka Y. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830
  CrossrefPubMedGoogle Scholar
• 19 Brown JN, Kemp DW, Brice KR. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009; 29: 468-472
  CrossrefPubMedGoogle Scholar
• 20 Katz O, Stuible M, Golishevski N, Lifshitz L, Tremblay ML, Gassmann M, Mittelman M, Neumann D. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010; 205: 87-95
  CrossrefPubMedGoogle Scholar
• 21 Czech MP, Buxton JM. Insulin action on the internalisation of the GLUT4 glucose transporter in isolated rat adipocytes. J Biol Chem 1993; 268: 9187-9190
  PubMedGoogle Scholar
• 22 Fisher MD, Frost SC. Translocation of GLUT1 does not account for elevated glucose transport in glucose-deprived 3T3-L1 adipocytes. J Biol Chem 1996; 271: 11806-11809
  CrossrefPubMedGoogle Scholar
• 23 Rigalleau V, Blanchetier V, Aparicio M, Baillet L, Sneed J, Dabadie H, Gin H. Erythropoietin can deteriorate glucose control in uraemic non-insulin-dependent diabetic patients. Diabetes Metab 1998; 24: 62-65
  PubMedGoogle Scholar
• 24 Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick E. The effect of iron and erythropoietin treatment on the HbA1c of patients with diabetes mellitus and chronic kidney disease. Diabetes Care 2010; 33: 2310-2313
  CrossrefPubMedGoogle Scholar
• 25 Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005; 15: 146-155
  CrossrefPubMedGoogle Scholar
• 26 Burén J, Liu HX, Lauritz J, Eriksson JW. High glucose and insulin in combination cause insulin receptor substrate-1 and -2 depletion and protein kinase B desensitisation in primary cultured rat adipocytes: possible implications for insulin resistance in type 2 diabetes. Eur J Endocrinol 2003; 148: 157-167
  CrossrefPubMedGoogle Scholar
• 27 Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1997; 94: 4171-4175
  CrossrefPubMedGoogle Scholar
• 28 Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, Morita Y, Kobara M, Nakata T. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009; 612: 106-114
  CrossrefPubMedGoogle Scholar
• 29 Rasic-Milutinovic Z, Perunicic-Pekovic G, Cavala A, Gluvic Z, Bokan L, Stankovic S. The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis. Hippokratia 2008; 12: 157-161
  PubMedGoogle Scholar
• 30 Cayla J, Lavoie C, Gareau R, Duvallet A. Effects of recombinant erythropoietin (r-HuEPO) on plasma glucose concentration in endurance-trained rats. Acta Physiol Scand 1999; 166: 247-249
  CrossrefPubMedGoogle Scholar